PNC Financial Services Group Inc. Has $5.74 Million Stake in Sanofi $SNY

PNC Financial Services Group Inc. boosted its holdings in Sanofi (NASDAQ:SNY) by 1.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 118,888 shares of the company’s stock after purchasing an additional 2,091 shares during the period. PNC Financial Services Group Inc.’s holdings in Sanofi were worth $5,744,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Capital Analysts LLC boosted its stake in shares of Sanofi by 14.0% during the 1st quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock worth $92,000 after buying an additional 204 shares during the last quarter. Thomasville National Bank raised its holdings in Sanofi by 0.3% during the second quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock worth $3,886,000 after acquiring an additional 211 shares in the last quarter. U.S. Capital Wealth Advisors LLC raised its stake in shares of Sanofi by 4.1% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 6,227 shares of the company’s stock worth $301,000 after purchasing an additional 247 shares in the last quarter. Whipplewood Advisors LLC raised its holdings in shares of Sanofi by 18.2% in the 2nd quarter. Whipplewood Advisors LLC now owns 1,606 shares of the company’s stock valued at $78,000 after purchasing an additional 247 shares during the period. Finally, Cetera Trust Company N.A lifted its stake in Sanofi by 4.2% in the 2nd quarter. Cetera Trust Company N.A now owns 6,140 shares of the company’s stock valued at $297,000 after purchasing an additional 250 shares during the last quarter. 14.03% of the stock is owned by institutional investors.

Sanofi Stock Performance

SNY opened at $52.14 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.94. The business has a fifty day simple moving average of $49.00 and a 200 day simple moving average of $49.40. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The company has a market capitalization of $128.03 billion, a PE ratio of 12.21, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 24th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.10. The company had revenue of $14.53 billion during the quarter, compared to the consensus estimate of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The company’s revenue was down 7.5% on a year-over-year basis. During the same quarter last year, the firm earned $2.25 earnings per share. Research analysts expect that Sanofi will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on SNY shares. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research note on Tuesday, November 11th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Finally, Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $56.00 to $58.00 in a research report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Sanofi has an average rating of “Buy” and a consensus price target of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.